Understanding radiology findings is essential for accurate diagnosis and effective treatment decisions. However, in today’s globalized world, patients increasingly present medical reports, including radiology findings, written in languages unfamiliar to their healthcare providers. These language barriers can hinder the integration of vital medical data into the clinical workup, leading to delays in diagnosis and suboptimal patient care [1]. Providing radiology reports in a language that healthca…
We scan the top radiology sources so you don’t have to.
From AI breakthroughs to imaging trends, we serve up real-time radiology insights.
-
Performance of AI-Based software in predicting malignancy risk in breast lesions identified on targeted ultrasound
Targeted ultrasound is commonly used to identify lesions characterized on magnetic resonance imaging (MRI) that were not recognized on initial mammography or ultrasound and is especially valuable for guiding percutaneous biopsies. Although artificial intelligence (AI) algorithms have been used to differentiate benign from malignant breast lesions on ultrasound, their application in classifying lesions on targeted ultrasound has not yet been studied.
-
Exploring the correlation between effective dose and BMI-based size-specific dose estimate in CT angiography
Computed tomography angiography (CTA) is a widely used diagnostic tool, but concerns about radiation exposure necessitate accurate dose estimation. This study investigates the correlation between Effective Dose (ED) and Size-Specific Dose Estimate (SSDE) estimated from the patient’s body mass index (BMI) in CTA to evaluate the utility of SSDE-BMI as a patient-specific dosimetry parameter.
-
Diagnostic Imaging's Weekly Scan: July 20 — July 26
Catch up on the top radiology content of the past week.
-
Week in Review: Post-COVID CT | SCCT 2025 coverage | Minnies nominations open
Best practices for post-COVID imaging and coverage of SCCT 2025 drew the most attention on AuntMinnie last week.
-
Background parenchymal enhancement as a predictor of invasive disease-free survival in hormone receptor-positive, HER2-negative breast cancer
The Oncotype DX assay (Genomic Health), a commercially available 21-gene breast cancer recurrence score (RS) assay, is one of several gene-expression assays that are used to predict prognosis in hormone receptor-positive breast cancer [1]. The Oncotype DX assay provides RS values ranging from 0 to 100, with higher scores indicating a worse prognosis and a greater likelihood of benefiting from chemotherapy [2]. A high RS, defined as 31 or higher (or 26 or higher in some cases), suggests a potenti…
-
Jul 25 2025 This Week in Cardiology
The VENTOUX study of endurance athletes, the 10,000 step myth was not busted, rate vs rhythm control for AF, and GLP1 drugs and observational studies are the topics John Mandrola, MD, discusses in this week’s podcast. theheart.org on Medscape
-
CATALYST: A Novel Approach to Treating Diabetes
Drs Akshay Jain and Vivian Fonseca discuss the CATALYST trial. Medscape Diabetes & Endocrinology
-
The Reading Room Podcast: A Closer Look at Remote MRI Safety, Part 2
In the second of a multi-part podcast episode, Emanuel Kanal, M.D. and Tobias Gilk, MRSO, MRSE, share their perspectives on remote MRI safety protocols for ensuring screening accuracy and adherence to conditional implant guidelines as well as a rapid and effective response to adverse events.
-
Body Composition Analysis in HF: Time to Replace BMI?
A recent meta-analysis prompts consideration of measurements of visceral and subcutaneous adiposity to better estimate cardiovascular risk than BMI. Journal of the American College of Cardiology